You are here: Industry Insights > Brii Bio

News List

Brii Bio Doses First Patient in Phase 2a/2b Clinical Trial of BRII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B prnasia
December 28, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Brii Bio’s tests show combo therapy retains activity against Omicron Pharmaceutical-Technology
December 14, 2021
Brii Biosciences has reported that its combination therapy of non-competing Covid-19 monoclonal antibodies (mAb), amubarvimab and romlusevimab (BRII-196/BRII-198)...
Brii Bio Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant prnasia
December 13, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China prnasia
December 09, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Brii Bio Receives the BioCentury-BayHelix R&D Achievement of the Year Award at the 2021 BioCentury China Healthcare Summit prnasia
November 18, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Brii Bio Initiates Submission of Emergency Use Authorization Filing to U.S. FDA for BRII-196/BRII-198, its Monoclonal Antibody Combination Therapy for Non-Hospitalized COVID-19 Patients at High Risk o prnasia
October 13, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Brii Bio Appoints Coy Stout as Senior Vice President and Head of U.S. Market Access and Patient Advocacy prnasia
September 28, 2021
Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical needs and large public health burdens...
Tsinghua and partners to develop neutralising antibodies against COVID-19 pharmaceutical-business-review
April 03, 2020
Tsinghua University has joined forces with 3rd People’s Hospital of Shenzhen and Brii Biosciences (Brii Bio) to develop neutralising antibodies against COVID-19 (novel coronavirus).
Brii Bio raises $260M to bring drugs to China biospectrumasia
May 28, 2018
Brii, which plans to combine partnerships, R&D and digital/big data, will use WuXi AppTec and WuXi biologics for development of its projects, rather than building its own facilities.